KM

Kestra Medical Technologies, Ltd.

KMTS·NASDAQ

$18.82

-6.8%
HealthcareMedical - Instruments & Supplies

Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its Cardiac Recovery System platform is the ASSURE WCD, a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). The company's Cardiac Recovery System platform also includes a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes. The company was founded in 2014 and is based in Kirkland, Washington.

At a Glance

Live Snapshot
Market Cap$1.10B
EPS-5.1300
P/E Ratio-3.67
Earnings Date07/21/2026
k

Kestra Medical Technologies, Ltd. Street Expectations Map

KMTS · NASDAQ

Wall Street analysts project that KMTS stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 28.00, with estimates ranging from a low of 24.00 to a high of 30.00.

Lowest Target
24.00
27.52%
Consensus Target
28.00
48.78%
Highest Target
30.00
59.40%

The consensus 1-year price target stands at 28.00, with estimates ranging from a low of 24.00 to a high of 30.00.

Analyst Consensus Analysis

Upside Potential

+48.8%

Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.

Analyst Agreement

21.4% spread

Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.

Analyst Conviction

Very High

Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.

Market Sentiment Insight

Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.

k

Kestra Medical Technologies, Ltd. Forward Estimates of Revenue

KMTS · NASDAQ
Latest Revenue
59.81M
FY 2025
Avg Estimate
92.97M
FY 2026
Estimate Range
92.96M - 94.04M
Analyst Spread

Forward Growth Analysis

Projected Growth+55.4%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage5 Analysts

Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.

Estimate Spread1%

Narrow estimate range signals strong analyst consensus and predictable business outlook.

OutlookStrong

Positive analyst consensus with strong growth expectations and forecast confidence.

Key Insight

Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.

k

Kestra Medical Technologies, Ltd. Forward Estimates of Net Income

KMTS · NASDAQ
Latest Net Income
-113.81M
FY 2025
Avg Estimate
-115.80M
FY 2026
Estimate Range
-117.53M - -114.06M
Analyst Spread

Forward Growth Analysis

Projected Growth-1.7%

Declining expectations indicate headwinds—investigate whether temporary or structural issues.

Analyst Coverage5 Analysts

Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.

Estimate Spread3%

Narrow estimate range signals strong analyst consensus and predictable business outlook.

OutlookNeutral

Mixed signals—some positive indicators offset by concerns about growth or uncertainty.

k

Kestra Medical Technologies, Ltd. Forward Estimates of EPS

KMTS · NASDAQ
Latest EPS
-5.13
FY 2025
Avg Estimate
$-2.34
FY 2026
Estimate Range
$-2.37 - $-2.30
Analyst Spread

Forward Growth Analysis

Projected Growth+54.3%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage4 Analysts

Limited coverage may indicate reduced institutional interest or information availability.

Estimate Spread3%

Narrow estimate range signals strong analyst consensus and predictable business outlook.

OutlookStrong

Positive analyst consensus with strong growth expectations and forecast confidence.

Key Insight

Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.

k

Kestra Medical Technologies, Ltd. Forward Estimates of EBIT

KMTS · NASDAQ
Latest EBIT
-105.94M
FY 2025
Avg Estimate
-18.59M
FY 2026
Estimate Range
-18.81M - -18.59M
Analyst Spread

Forward Growth Analysis

Projected Growth+82.4%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage5 Analysts

Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.

Estimate Spread1%

Narrow estimate range signals strong analyst consensus and predictable business outlook.

OutlookStrong

Positive analyst consensus with strong growth expectations and forecast confidence.

Key Insight

Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.

k

Kestra Medical Technologies, Ltd. Forward Estimates of EBITDA

KMTS · NASDAQ
Latest EBITDA
-97.98M
FY 2025
Avg Estimate
-18.59M
FY 2026
Estimate Range
-18.81M - -18.59M
Analyst Spread

Forward Growth Analysis

Projected Growth+81.0%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage5 Analysts

Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.

Estimate Spread1%

Narrow estimate range signals strong analyst consensus and predictable business outlook.

OutlookStrong

Positive analyst consensus with strong growth expectations and forecast confidence.

Key Insight

Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.

k

Kestra Medical Technologies, Ltd. Forward Estimates of SG&A Expense

KMTS · NASDAQ
Latest SG&A Expense
114.94M
FY 2025
Avg Estimate
251.31M
FY 2026
Estimate Range
251.28M - 254.18M
Analyst Spread

Forward Growth Analysis

Projected Growth+118.6%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage5 Analysts

Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.

Estimate Spread1%

Narrow estimate range signals strong analyst consensus and predictable business outlook.

OutlookStrong

Positive analyst consensus with strong growth expectations and forecast confidence.

Key Insight

Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.

k

Kestra Medical Technologies, Ltd. Insider Positioning

KMTS · NASDAQ

During the last 12 months, insiders have purchased $200K and sold $2.09M worth of KMTS shares, resulting in $1.89M of net selling activity.

3 Months

Bought

10.0K

199.80K

Sold

38.2K

772.20K

Net Activity

-572K

-$572K

3-6 Months

Bought

0

0.00

Sold

52.1K

1.32M

Net Activity

-1.3M

-$1.32M

6-9 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

9-12 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

Top Buyers

1
CRW

Cohen Raymond W

Director

10.0K shares1 transactions

$200K

Top Sellers

1
WBD

Webster Brian Daniel

Director, Officer: See Remarks

79.8K shares6 transactions

$1.81M

2
UTS

Umberger Traci S

Director, Officer: See Remarks

10.5K shares1 transactions

$280K

Insider Activity Analysis

Net Insider Sentiment

Bearish

Strong bearish signal with $1.89M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.

Buy/Sell Ratio

0.10:1

Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.

Recent Trend (3 Months)

$572K

Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.

Insider Participation

Moderate Selling

2 insider sellers vs. 1 buyers. More insiders selling than buying suggests cautious or negative sentiment.

Insider Activity Insight

Persistent selling pressure: Consistent insider selling with weak buy/sell ratio suggests insiders may be capitalizing on current valuation. Exercise caution and review recent earnings quality and management commentary.